"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

260 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-09-30

Study Completion Date

2018-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Current methods based on traditional Cardiovascular risk factors are not clinically useful for identifying Type 2 Diabetes patients at risk of developing acute Cardiovascular ischemic events (ie.myocardial infarction or stroke). In addition, Cardiovascular ischemic events in Type 2 Diabetes population have worse prognosis than in general population. In fact, there is sufficient experimental evidence indicating that diabetes exaggerates the deleterious effects of ischemic events and worsens their outcome.

A prolonged sub-clinical phase exists before a Cardiovascular event occurs in Type 2 Diabetes patients. Therefore, new strategies aimed at identifying those patients with this subclinical Cardiovascular Diabetes and, consequently, more prone to develop Cardiovascular events is a challenge to be met.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiovascular Risk Assesment in Diabetic Patients Via Lens Autofluorecscence Detection

NCT02947555

Diabetic Patients With/Without Atherosclerotic Diseases

UNKNOWN

Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects

NCT01843114

Type I Diabetes

COMPLETED NA

Cardiovascular Risk Assessment in a Cohort of Italian Patients With Type 1 Diabetes Mellitus (CARDT1)

NCT06290544

Diabetes Mellitus, Type 1 Cardiovascular Diseases

RECRUITING NA

Coronary CT Angiography in Asymptomatic Diabetes Mellitus

NCT00321542

Diabetes Mellitus

UNKNOWN

DD2-Coronary Plaque Morphology and Plaque Progression

NCT03022344

Diabetes Plaque Atherosclerosis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives

1\) To examine whether the extension and degree of microangiopathy is an independent risk factor for silent myocardial and brain ischemia. 2) To evaluate whether the degree and extension of microangiopathy is a predictor of CV events and poor outcome. 3) To evaluate whether a new score based on the extension and the degree of microangiopathy will permit us to improve the current methods used to identify patients at risk of CVD and its outcomes. 4) To determine whether the presence and the degree of NAFLD is an independent Cardiovascular disease risk factor and represent and extra-value to the score based on the extension and the degree of microangiopathy.

Secondary objectives:

1\) To examine the usefulness of selected serum biomarkers in identifying diabetic patients at risk of Cardiovascular disease 2) To evaluate whether these selected biomarkers are related to the degree and extension of microangiopathy and the outcome of cardiovascular events. 3) To better define the meaning of microalbuminuria in type 2 diabetic population (glomerular involvement vs. index of generalized endothelial dysfunction)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type2 Diabetes Mellitus Microangiopathy Non Alcoholic Fatty Liver Disease Coronary Artery Disease Cerebrovascular Disease Acute Coronary Syndrome/ Myocardial Infarction Ictus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients/Control Group

Observational

No interventions assigned to this group

Patients/Group Control

Observational

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a) Age from 50-79 years; b) History of type 2diabetes of at least one year. Diabetes will be defined following the American Diabetic Association criteria: fasting glucose level of at least 126 mg/dl \[7.0 mmol/l\] in two separate analyses, a non-fasting glucose level of at least 200 mg/dl \[11.1 mmol/l\] or a self-reported history of physician-diagnosed diabetes or treatment for diabetes

Exclusion Criteria

* a) Past medical history of Cardiovascular event; b) Type 1 diabetes; c) Contraindication for PET-CT or MRI d) Other concomitant disease associated with a short life expectancy

Minimum Eligible Age

50 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes